Skip to main content
British Medical Journal logoLink to British Medical Journal
. 1975 Sep 13;3(5984):626–628. doi: 10.1136/bmj.3.5984.626

Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy.

D D Munro, L Wilson
PMCID: PMC1674413  PMID: 1164639

Abstract

Clobetasone butyrate is a new corticosteroid, selected for study because of its combination of good activity in the vasoconstriction test and low systemic activity in animals. Formulated as an 0.05% ointment and cream (Molivate) it was clinically effective in patients with eczema, its activity being significantly greater than that of hydrocortisone 1% or fluocortolone 0.2% (Ultradil). Under conditions that predispose to maximal percutaneous absorption clobetasone butyrate ointment had minimal effect on hypothalamic-pituitary-adrenal function. In an animal model of cutaneous atrophy it caused less thinning of the epidermis than steroids other than hydrocortisone. Clobetasone butyrate 0.05% ointment and cream gave every indication of offering clinically effective topical anti-inflammatory activity with a wide margin of safety.

Full text

PDF
626

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Child K. J., English A. F., Gilbert H. G., Hewitt A., Woollett E. A. Vasoconstrictor and systemic activities of topical steroids. Arch Dermatol. 1968 Apr;97(4):407–410. [PubMed] [Google Scholar]
  2. Feinblatt B. I., Aceto T., Jr, Beckhorn G., Bruck E. Percutaneous absorption of hydrocortisone in children. Am J Dis Child. 1966 Sep;112(3):218–224. doi: 10.1001/archpedi.1966.02090120086008. [DOI] [PubMed] [Google Scholar]
  3. James V. H., Munro D. D., Feiwel M. Pituitary-adrenal function after occlusive topical therapy with betamethasone-17-valerate. Lancet. 1967 Nov 18;2(7525):1059–1061. doi: 10.1016/s0140-6736(67)90336-4. [DOI] [PubMed] [Google Scholar]
  4. Sparkes C. G., Wilson L. The clinical evaluation of a new topical corticosteroid, clobetasol propionate. An international controlled trial. Br J Dermatol. 1974 Feb;90(2):197–203. doi: 10.1111/j.1365-2133.1974.tb06385.x. [DOI] [PubMed] [Google Scholar]
  5. Tan R. S. Pustular psoriasis with adrenal suppression following topical corticosteroids. Proc R Soc Med. 1974 Aug;67(8):719–720. doi: 10.1177/003591577406700813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. WILLIAMS D. I., WILKINSON D. S., OVERTON J., MILNE J. A., MCKENNA W. B., LYELL A., CHURCH R. BETAMETHASONE 17-VALERATE: A NEW TOPICAL CORTICOSTEROID. Lancet. 1964 May 30;1(7344):1177–1179. doi: 10.1016/s0140-6736(64)91205-x. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES